APLS | Apellis Pharmaceuticals, Inc. |
Pharmaceutical Preparations |
Book value per $ invested | $ 0.06 |
Leverage | 73.71% |
Market Cap | $ 4.1B |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -291.2m |
Margin | -43.87% |
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.